"In In re McLeay, the Federal Circuit affirms the rejection of COVID-19 treatment claims, marking a pivotal shift in utility and enablement standards in patent law."
"The ruling illustrates that the Full Scope Enablement Doctrine is taking the lead in determining useful inventions, particularly within pharmaceutical treatment claims."
The Federal Circuit's decision in In re McLeay reveals significant changes in patent law regarding utility and enablement, particularly for pharmaceutical treatment claims. The court confirmed the USPTO's rejection of patent claims for treating COVID-19 with aerosolized ribavirin. This ruling highlights a shift where the Full Scope Enablement Doctrine has taken on responsibilities traditionally associated with the Utility Doctrine, focusing on ensuring the practical usefulness of inventions, a role the Utility Doctrine has failed to maintain effectively in recent years. The case was notably argued by the applicant's twin brother, further underscoring its personal significance.
Read at Patently-O
Unable to calculate read time
Collection
[
|
...
]